The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration

Behavioural Brain Research

Volumn 177, Issue 1, 2007, Pages 150-159

  Lindgren, Hanna S ^a   Rylander, Daniella ^a   Ohlin, K Elisabet ^a   Lundblad, Martin ^a   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

6 OHDA; l DOPA; Motor complications; Parkinson's disease; Striatum; Toxicity

Indexed keywords

BENSERAZIDE; BROMOCRIPTINE; LEVODOPA; OXIDOPAMINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DYSKINESIA; FEMALE; LOCOMOTION; LOW DRUG DOSE; MICROGLIA; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN INJURIES; BROMOCRIPTINE; CELL COUNT; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; IMMUNOHISTOCHEMISTRY; LEVODOPA; LIPOPOLYSACCHARIDES; MOVEMENT DISORDERS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33845976016     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.09.019     Document Type: Article

References (56)

1. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 Suppl. 2 (1994) S32-S44
2. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 2 (1990) 340-345
3. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 8 (1998) 2694-2706
4. Lundblad M., et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15 (2002) 120-132
5. Lee C.S., et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 Pt 7 (2000) 1365-1379
6. Picconi B., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6 5 (2003) 501-506
7. Engber T.M., et al. Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience 59 2 (1994) 389-399
8. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioural responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151 2 (1998) 334-342
9. Marin C., et al. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192 1 (2005) 184-193
10. Marin C., et al. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 36 4 (2000) 267-274
11. Marin C., et al. MK-801 prevents levodopa-induced motor response alterations in Parkinsonian rats. Brain Res 736 1-2 (1996) 202-205
12. Papa S.M., et al. Reversal of levodopa-induced motor fluctuations in experimental Parkinsonism by NMDA receptor blockade. Brain Res 701 1-2 (1995) 13-18
13. Papa S.M., et al. Motor fluctuations in levodopa treated Parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662 1-2 (1994) 69-74
14. Mura A., Mintz M., and Feldon J. Behavioural and anatomical effects of long-term l-dihydroxyphenylalanine (l-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177 1 (2002) 252-264
15. Silverman P.B. Sensitisation, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat. Eur J Pharmacol 229 2-3 (1992) 235-240
16. Silverman P.B. On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat. Eur J Pharmacol 242 1 (1993) 31-36
17. Marin C., Rodriguez-Oroz M.C., and Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp Neurol 197 2 (2006) 269-274
18. Tomiyama M., et al. Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with l-DOPA: implication for l-DOPA-induced dyskinesia in Parkinson's disease. Neuropathology 24 4 (2004) 290-295
19. Van Kampen J.M., and Stoessl A.J. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience 98 1 (2000) 61-67
20. Carta M., et al. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96 6 (2006) 1718-1727
21. Westin J.E., et al. Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14 7 (2001) 1171-1176
22. Winkler C., et al. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10 2 (2002) 165-186
23. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 6 (1999) 461-474
24. Da Prada M., et al. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 27 Suppl. 1 (1987) 9-20
25. Grange S., Holford N.H., and Guentert T.W. A pharmacokinetic model to predict the PK interaction of l-DOPA and benserazide in rats. Pharm Res 18 8 (2001) 1174-1184
26. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231 4 (1991) 482-497
27. Igarashi K., et al. Determination of cabergoline and l-DOPA in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 792 1 (2003) 55-61
28. Djaldetti R., Ziv I., and Melamed E. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci 32 12 (1996) 1224-1227
29. Kurlan R., et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 38 3 (1988) 419-421
30. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 Pt 11 (2000) 2297-2305
31. Olanow C.W., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 9 (2004) 997-1005
32. Zhang Z., et al. Lesional accumulation of P2X4 receptor + monocytes following experimental traumatic brain injury. Exp Neurol 197 1 (2006) 252-257
33. Semmler A., et al. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat 30 2-3 (2005) 144-157
34. Depino A.M., et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18 10 (2003) 2731-2742
35. Herrera A.J., et al. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7 4 (2000) 429-447
36. Metman L.V., Konitsiotis S., and Chase T.N. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 15 1 (2000) 3-8
37. Guttner J. Complications and effects of the intraperitoneal application in animal experiment. Pharmazie 30 3 (1975) 129-133
38. Djaldetti R., Atlas D., and Melamed E. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Clin Neuropharmacol 19 1 (1996) 65-71
39. Konradi C., et al. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis 17 2 (2004) 219-236
40. Meissner W., et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine. Neurobiol Dis 22 3 (2006) 586-598
41. Taylor J.L., et al. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 50 6 (2006) 761-768
42. Monville C., Torres E.M., and Dunnett S.B. Validation of the l-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 68 1-2 (2005) 16-23
43. Steece-Collier K., et al. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats. Mov Disord 18 12 (2003) 1442-1454
44. Stefanova N., et al. Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 15 3 (2004) 630-639
45. Pinna A., Pontis S., and Morelli M. Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res 171 1 (2006) 175-178
46. Bibbiani F., et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196 2 (2005) 422-429
47. Oh J.D., Bibbiani F., and Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate Parkinsonian models. Exp Neurol 177 2 (2002) 557-564
48. Marin C., et al. Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. Exp Neurol 183 1 (2003) 66-73
49. Marin C., et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 42 1 (2001) 40-47
50. Marin C., et al. Bilateral subthalamic nucleus lesion reverses l-DOPA-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse 51 2 (2004) 140-150
51. Blunt S.B., Jenner P., and Marsden C.D. Suppressive effect of l-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8 2 (1993) 129-133
52. Camp D.M., Loeffler D.A., and LeWitt P.A. l-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 74 3 (2000) 1229-1240
53. Mena M.A., et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7 1 (1992) 23-31
54. Mena M.A., et al. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 4 4 (1993) 438-440
55. Murer M.G., et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43 5 (1998) 561-575
56. Mytilineou C., Han S.K., and Cohen G. Toxic and protective effects of l-DOPA on mesencephalic cell cultures. J Neurochem 61 4 (1993) 1470-1478